Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period.
Kelly J GaffneyTheresa A UrbanMariana LucenaLisa RybickiNavneet S MajhailSherif Beniameen MossadPublished in: Clinical hematology international (2023)
The use of TMP-SMX was associated with a higher likelihood of bacteremia and hyperkalemia; however, this did not result in increased hospital stay, escalation of care, or mortality. The use of TMP-SMX for prophylaxis during the pre-engraftment period for allo-HCT recipients is safe and effective.
Keyphrases
- hematopoietic stem cell
- healthcare
- palliative care
- cardiovascular events
- risk factors
- quality improvement
- open label
- gram negative
- pain management
- kidney transplantation
- emergency department
- acute care
- type diabetes
- antibiotic resistance genes
- multidrug resistant
- cell cycle arrest
- affordable care act
- study protocol
- cord blood